Cytokinetics, Incorporated filed a Current Report on Form 8-K on August 28, 2026, announcing the presentation of full results from its ACACIA-HCM trial at the European Society of Cardiology Congress 2026 and simultaneous publication in the New England Journal of Medicine.

Key Highlights

  • Trial results disclosed: Full results of ACACIA-HCM were presented at the ESC Congress 2026, according to the filing.
  • Journal publication: The results were also published in the New England Journal of Medicine, the company disclosed.
  • Event date: The announcement and press release were both dated August 28, 2026.
  • Filing type: The report was filed under Item 8.01 (Other Events), with the full press release incorporated as Exhibit 99.1.
  • Exchange listing: Cytokinetics common stock ($0.001 par value) trades on NASDAQ:CYTK on The Nasdaq Global Select Market.

Cytokinetics Discloses ACACIA-HCM Data at ESC Congress and in NEJM

According to the filing, Cytokinetics, Incorporated issued a press release on August 28, 2026, reporting that the full results of ACACIA-HCM were presented at the European Society of Cardiology (ESC) Congress 2026. The company also disclosed that these results were published concurrently in the New England Journal of Medicine. The 8-K does not detail the specific clinical findings; the complete disclosure is contained in Exhibit 99.1, the press release incorporated by reference into the filing.

The filing was made under Item 8.01 (Other Events) of Form 8-K, which the registrant used to communicate the event to investors and the public. Cytokinetics is incorporated in Delaware and is headquartered at 350 Oyster Point Boulevard, South San Francisco, California 94080, as stated on the cover page. The registrant confirmed it is not an emerging growth company. The filing was signed by John O. Faurescu, SVP, Deputy General Counsel and Secretary, on behalf of Cytokinetics, Incorporated.

No financial statements were included in connection with this filing. The only exhibit listed is Exhibit 99.1, the press release dated August 28, 2026. The cover page was formatted in Inline XBRL, as noted in the filing under Item 9.01.

What Was Disclosed

Cytokinetics filed an 8-K on August 28, 2026, announcing the presentation of full ACACIA-HCM trial results at the ESC Congress 2026 and their simultaneous publication in the New England Journal of Medicine, with the full press release attached as Exhibit 99.1.